Julio Chavez, MD, MS
Dr. Chavez is an Associate Member in the Lymphoma Section of the Department of Malignant Hematology at Moffitt Cancer Center. He did his Internal Medicine training at the State University of New York in Buffalo, New York and completed his Medical Oncology training at the University of South Florida/Moffitt Cancer Center. Dr. Chavez is board-certified in Internal Medicine and Medical Oncology. His focus of clinical and research interests is in lymphoid malignancies, specifically aggressive lymphomas, virally-related lymphoid malignancies and chronic lymphocytic leukemia. His research is focused in immunotherapy, specially cell immunotherapy. He is currently Principal Investigator in several clinical trials using targeted agents and immunotherapy. He is not only well versed in standard therapies, but he is an active participant in clinical research; and therefore, is able to offer his patients and their families the best treatment options tailored specifically to each patient. Dr. Chavez joined Moffitt Cancer Center in 2013.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:KiteTopic:ConsultingDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:NovartisTopic:ConsultingDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:BMS/CelgeneTopic:ConsultingDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:GenMabTopic:ConsultingDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:MerckTopic:Research supportDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:JannsenTopic:Research SupportDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AstraZenecaTopic:Research SupportDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:AllogeneTopic:ConsultingDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:BeigeneTopic:HonorariaDate added:01/22/2024Date updated:01/22/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:LillyTopic:HonorariaDate added:01/22/2024Date updated:01/22/2024